Pylorus-Preserving Pancreatoduodenectomy. Experience in 20 Patients
Autor: | Leslie H. Blumgart, Philippe Gertsch, L. Krähenbiühl, Jan Lerut, P. J. Luder |
---|---|
Jazyk: | angličtina |
Rok vydání: | 1991 |
Předmět: |
Adult
Male Peptic Ulcer medicine.medical_specialty Pancreatic disease medicine.medical_treatment lcsh:Surgery Scintigraphy Pancreaticoduodenectomy Median follow-up medicine Humans Postoperative Period lcsh:RC799-869 Pylorus Aged Hepatology Gastric emptying medicine.diagnostic_test business.industry lcsh:RD1-811 Middle Aged medicine.disease Marginal Ulcer Surgery Pancreatic Neoplasms medicine.anatomical_structure Bile Duct Neoplasms Gastric Emptying Pancreatitis Female lcsh:Diseases of the digestive system. Gastroenterology business Research Article |
Zdroj: | HPB Surgery, Vol 4, Iss 2, Pp 109-119 (1991) HPB Surgery |
ISSN: | 0894-8569 |
Popis: | Twenty patients underwent a pylorus-preserving pancreatoduodenectomy for benign or malignant periampullary and pancreatic disease. Eighteen patients had a partial and two patients a total pancreatectomy. There were 19 elective and 1 emergency operations.Post-operative mortality was 4% (1/20 patients) and the median follow up was 31 months (range, 15– 75 months), during which period 8 patients with a malignant disease died.Pylorus-preserving pancreatoduodenectomy did not compromise survival in ampullary cancer.One patient developed a marginal ulcer during the study period and one of twelve patients, examined by technetium scintigraphy (done more than 3 months after the procedure), had delayed gastric emptying. Two patients presented with a gastric retention as the first sign of recurrent pancreatic cancer.The result of the operation was judged as excellent in 7 patients, good in 8 and as bad in only 2 of the 17 patients who survived more than 6 months . Body weight was studied in 15 patients surviving more than one year after operation; five patients had gained weight, two had lost weight and in 8 there was no difference.Pylorus-preserving pancreatoduodenectomy seems to be a valuable alternative in the treatment of patients with benign and selected malignant pancreaticobiliary disease. |
Databáze: | OpenAIRE |
Externí odkaz: |